Sage TherapeuticsSAGE
SAGE
About: Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
Employees: 487
0
Funds holding %
of 7,323 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
100% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 2 (+1) [Q1 2025]
62% more first-time investments, than exits
New positions opened: 60 | Existing positions closed: 37
48% more capital invested
Capital invested by funds: $278M [Q4 2024] → $411M (+$133M) [Q1 2025]
13% more funds holding
Funds holding: 176 [Q4 2024] → 198 (+22) [Q1 2025]
0.44% more ownership
Funds ownership: 83.74% [Q4 2024] → 84.18% (+0.44%) [Q1 2025]
6% less repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 53
20% less call options, than puts
Call options by funds: $2.1M | Put options by funds: $2.63M
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$8.50
2%
downside
Avg. target
$9.37
8%
upside
High target
$12
38%
upside
6 analyst ratings
0 positive
0%
6 neutral
100%
0 negative
0%
Scotiabank George Farmer | 6%upside $9.20 | Sector Perform Downgraded | 8 Jul 2025 |
Baird Joel Beatty | 4%upside $9 | Neutral Maintained | 20 Jun 2025 |
Piper Sandler David Amsellem | 2%downside $8.50 | Neutral Downgraded | 17 Jun 2025 |
Truist Securities Joon Lee | 4%upside $9 | Hold Maintained | 17 Jun 2025 |
HC Wainwright & Co. Douglas Tsao | 38%upside $12 | Neutral Reiterated | 17 Jun 2025 |
Financial journalist opinion
Based on 5 articles about SAGE published over the past 30 days
Neutral
Zacks Investment Research
6 hours ago
Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Beats Revenue Estimates
Sage Therapeutics, Inc. (SAGE) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.96. This compares to a loss of $1.7 per share a year ago.
Neutral
Business Wire
8 hours ago
Sage Therapeutics Announces Second Quarter 2025 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the second quarter ended June 30, 2025. “Our second quarter results reflect revenue acceleration driven by increased investment, strong execution, and growing momentum behind ZURZUVAE, underscoring our collective commitment to advancing care for women with postpartum depression,” said Barry Greene, Chief Executive Officer at Sage Therapeutics. “As we work with.
Neutral
Business Wire
2 weeks ago
SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Sage Therapeutics, Inc. (NasdaqGM: SAGE) to Supernus Pharmaceuticals, Inc. (NasdaqGM: SUPN). Under the terms of the proposed transaction, Sage shareholders will receive $8.50 per share in cash, plus one non-tradable contingent value right collectively worth up to $3.50 per share in cash payable upon.
Neutral
GlobeNewsWire
4 weeks ago
$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Sage Therapeutics, Inc. (NASDAQ: SAGE)
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Sage Therapeutics, Inc. (NASDAQ: SAGE ) related to its sale to Supernus Pharmaceuticals, Inc. Upon completion of the proposed transaction, current Sage shareholders will receive $8.50 per share in cash, plus one non-tradable contingent value right collectively worth up to $3.50 per share in cash payable (i) $0.50 the first commercial sale of the drug Zurzuvae in Japan to third-aprty consumers following regulatory approval on or before June 30, 2026; (ii) $1.00 when net sales of Zurzuvae reach or exceed $300 million in the U.S. on or before December 31, 2028; and (iii) $1.00 when net sales of Zurzuvae reach or exceed $375 million in the U.S. on or before December 31, 2030. Is it a fair deal?
Positive
Zacks Investment Research
4 weeks ago
What Makes Sage Therapeutics (SAGE) a New Buy Stock
Sage Therapeutics (SAGE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neutral
GlobeNewsWire
1 month ago
Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary
FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced the appointment of Anne Marie Cook, J.D.
Neutral
Business Wire
1 month ago
SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Sage Therapeutics, Inc. (NasdaqGM: SAGE) to Supernus Pharmaceuticals, Inc. (NasdaqGM: SUPN). Under the terms of the proposed transaction, Sage shareholders will receive $8.50 per share in cash, plus one non-tradable contingent value right collectively worth up to $3.50 per share in cash payable upon.
Positive
Zacks Investment Research
1 month ago
SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal
SUPN inks deal to acquire Sage Therapeutics for up to $795 million, securing rights to depression drug Zurzuvae.
Neutral
Benzinga
1 month ago
These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News
Supernus Pharmaceuticals, Inc. SUPN on Monday agreed to acquire Sage Therapeutics, Inc. SAGE for $12.00 per share in cash, or an aggregate of up to approximately $795 million.
Positive
Zacks Investment Research
1 month ago
Sage Therapeutics (SAGE) Soars 35.4%: Is Further Upside Left in the Stock?
Sage Therapeutics (SAGE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Charts implemented using Lightweight Charts™